Double-digit growth in profits for the 18th consecutive year – dividend increase to CHF 14 per registered share proposed
Tuesday, 11 March 2014, ↓ directly to download
Galenica increased consolidated net sales by 2.0% to CHF 3,359.4 million in 2013. On a comparable basis, profit before deduction of minority interests increased by 7.8% to CHF 296.2 million and after deduction of minority interests by 1.6% to CHF 257.6 million. Taking into account positive one-time effects due to IAS 19 and the settlement of an international tax case, net profit saw a double-digit growth for the 18th consecutive year, by 21.1% to CHF 334.8 million before and by 16.1% to CHF 296.2 million after deduction of minority interests. At the Annual General Meeting 2014, the Board of Directors will recommend a dividend increase of 27.3% to CHF 14.00 per registered share.
_Among the highlights of 2013 were US Food and Drug Administration (FDA) approvals for Injectafer® for the treatment of iron deficiency anaemia and for Velphoro® to control serum phosphorus levels in patients with chronic kidney disease on dialysis. Further milestones were the acquisition of Medifilm, the leading Swiss company in the field of blister packaging for medicines, as well as the acquisition of a minority stake in the pharmacy Bahnhof Apotheke Zurich.
_In 2014, Vifor Pharma will continue to expand Ferinject® in international markets, will support its partner Luitpold Pharmaceuticals, Inc. with the launch of Injectafer® in the US and will prepare further registrations and the commercialisation of Velphoro®. Logistics, Retail and HealthCare Information will continue to expand their business activities and to implement the projects already launched in order to optimise processes and improve profitability.
_Galenica management has set itself the target of achieving at least the same level of profit in 2014 as in the previous year on a comparable basis, both before and after deduction of minority interests.
EBIT, EBITDA and consolidated net profit of the Galenica Group
in million CHF
Other and eliminations
_Shareholders of Galenica Ltd.
Galenica is a diversified Group active throughout the healthcare market which, among other activities, develops, manufactures and markets pharmaceutical products, runs pharmacies, provides logistical and database services and sets up networks. With its two Business units Vifor Pharma and Galenica Santé, the Galenica Group enjoys a leading position in all its core business activities. A large part of the Group’s income is generated by international operations. Galenica is listed on the Swiss Stock Exchange (SIX Swiss Exchange, GALN, security number 1,553,646).
Wednesday, 27 August 2014
Tuesday, 12 August 2014
Tuesday, 12 August 2014
Friday, 27 June 2014
Head Investor Relations
Head of Corporate Communications